Business
Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
REGULATED INFORMATION Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results U.S. Commercialization Off to a Strong Start in First Full Quarter of SalesFoundation Established to Drive Significant Growth in 2026 Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstruct
About this update from Nyxoah Sa
[{"type":"image","alt":"Nyxoah","displaySize":"","headline":null,"caption":"Nyxoah","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/f090b0134f1a96c88516737ccd77cad1"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FbfhsHKC3cqGVKfmi0y0gQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/f090b0134f1a96c88516737ccd77cad1","width":300,"height":116}},"lazy":false},{"type":"text","content":"REGULATED INFORMATION","length":21,"tagName":"p"},{"type":"text","content":"Nyxoah Reports Fourth Quarter and Full Year 2025 Financial and Operating Results","length":80,"tagName":"p"},{"type":"text","content":"U.S. Commercialization Off to a Strong Start in First Full Quarter of SalesFoundation Established to Drive Significant Growth in 2026 ","length":134,"tagName":"p"},{"type":"text","content":"Mont-Saint-Guibert, Belgium – March 19, 2026, 9:10pm CET / 4:10 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the fourth quarter and full year of 2025.","length":378,"tagName":"p"},{"type":"text","content":"Recent Financial and Operating Highlights ","length":41,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Fourth quarter gross revenue of €6.3 million, resulting in net revenue of €5.6 million, which represents 347% year-over-year growth, driven by the first full quarter of US commercialization","length":189,"tagName":"p"}]},{"val":[{"type":"text","content":"Full year gross revenue of €11.0 million, resulting in net revenue of €10.0 million, which represents 122% year-over-year growth","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Fourth quarter gross margin of approximately 64%","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and financial assets of €48.0 million at December 31, 2025","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"145 surgeons trained and 57 accounts activated in the U.S. since commercial launch in August 2025","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Genio system consistently reimbursed by ...